Sarepta sells international rights to Duchenne gene therapy to Roche

Sarepta sells international rights to Duchenne gene therapy to Roche

STAT Plus: Sarepta sells international rights to Duchenne gene therapy to Roche

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

For Roche, tying up with Sarepta deepens the Swiss pharma giant’s commitment to the field of gene therapy following its $4 billion acquisition of Spark.

READ MORE